ANADYS PHARMACEUTICALS

Anadys Pharmaceuticals is a biopharmaceutical company that develops novel therapeutics for the treatment of chronic hepatitis C viral infections. The company focuses on the development of ANA598, a direct-acting antiviral (DAA) for the treatment of hepatitis C. It also focuses to resume the clinical development of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll-like receptor 7 or TLR7. Anadys Pharmaceuticals was founded in 1992 and is headquartered in San Diego, California. As of November 22, 2011, Anadys Pharmaceuticals operates as a subsidiary of Hoffmann-La Roche Inc.